ReviewMetabolic syndrome and related disorders2018
Combination Therapies for Obesity.
Review in Metabolic syndrome and related disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Effect of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Fat Loss and Cardiorespiratory Fitness in the Young and Middle-Aged a Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2023Pooled it
- The impact of Aprepitant on Nausea and Vomiting following Laparoscopic Sleeve Gastrectomy: A Blinded Randomized Controlled Trial.Obesity surgery · 2024Trial
- Trial
- Trial
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- SERCA blockade as a treatment strategy for obesity.European journal of applied physiology · 2025Review
- Obesity Management Medications as Adjuncts to Metabolic and Bariatric Surgery: Consensus Recommendations from India.Obesity surgery · 2025Review
- Mobilizing Stockpile of Nature: Phytochemicals, Herbal Extracts, and Dietary Supplements for Managing Metabolic Diseases with Concentric Focus on Obesity.Endocrine, metabolic & immune disorders drug targets · 2025Review
- The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats.Acta neuropsychiatrica · 2024Article
- Weighing your options-intragastric balloon versus semaglutide.Surgical endoscopy · 2024Article
- From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.Molecular biology reports · 2024Review
- Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice.International journal of obesity (2005) · 2024Article
- Nutrition and Patient Follow-up in Bariatric Surgery.The Eurasian journal of medicine · 2023Article
- L-carnitine and Acetyl-L Carnitine: A Possibility for Treating Alterations Induced by Obesity in the Central Nervous System.Neurochemical research · 2023Review
- CCE and EODF as two distinct non-shivering thermogenesis models inducing weight loss.Pflugers Archiv : European journal of physiology · 2023Article
- A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity.Journal of the Endocrine Society · 2023Article
- Pharmaco-endoscopic therapy for weight regain post-gastric bypass: a case report.Journal of surgical case reports · 2023Article
- Revisional Single-Anastomosis Gastric Bypass for a Patient With Severe Protein-Calorie Malnutrition: A Case Report.Cureus · 2023Article
- One-anastomosis gastric bypass reversal due to severe malnutrition and acute hepatic failure: a case report.Journal of surgical case reports · 2023Article
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The objective of this review is to examine advances in the development of combination therapies for the treatment of obesity beyond diet or lifestyle interventions. Experimental combination pharmacotherapies include combinations of pramlintide and phentermine as well as amylin and bupropion-naltrexone. Incretin and pancreatic hormones generally inhibit upper gastrointestinal motor functions, and combinations showing efficacy in obesity are coadministration of glucagon-like peptide-1 (GLP-1) with glucagon, a unimolecular dual incretin of PEGylated GLP-1/GIP coagonist, the combination of GLP-1 and PYY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.